Auto Injector Union Medico

[Ashley]

On25 June 2015, the European Medicines Agency (EMA) recommended several measures, including the introduction of more effective educational material, to ensure that patients and carers use adrenaline auto-injectors successfully. Adrenaline auto-injectors are potentially life-saving treatments for anaphylaxis (severe allergic reactions) while the patient waits for emergency medical assistance.

EMA carried out a review of adrenaline auto-injectors following concerns that currently available devices may deliver adrenaline under the skin instead of into a muscle, and this may delay response to treatment.

Having assessed all the available data, EMA's Committee for Medicinal Products for Human Use (CHMP) acknowledged that giving the medicine by injection into the muscle is the preferred way to obtain a rapid response in anaphylaxis. However, the CHMP noted that several factors may affect whether adrenaline is actually delivered into a muscle; these include needle length, the thickness of fat under the skin, the way the auto-injector works (e.g. if it is spring loaded or not), the angle at which the device is placed on the skin and the force used to activate the device as well as how well the user follows the instructions for injection.

The CHMP concluded that training of the user is of paramount importance. The companies that market adrenaline auto-injectors have therefore been asked to develop more effective educational material for patients, as well as for healthcare professionals, to ensure their optimal use. This includes a training device with which patients can practise; audio-visual material to show in detail how the device is to be used; and a checklist for prescribers to ensure that sufficient information is given to the patient before they use the auto-injector. The product information of adrenaline auto-injectors has also been updated with further warnings and precautions, including a recommendation that patients should be prescribed two auto-injectors which they should carry at all times and a recommendation for family members, carers or teachers to be trained on how to use the auto-injector.

Adrenaline (epinephrine) auto-injectors are given to people who are at risk of anaphylaxis (severe allergic reaction) or have had a previous episode of anaphylaxis, to use as a first?aid measure in case of emergencies while waiting for emergency medical assistance.

Anaphylaxis is a life-threatening reaction that causes a drop in blood pressure and breathing difficulties. An injection of adrenaline helps to relieve the symptoms of anaphylaxis quickly by narrowing the blood vessels (thereby increasing the blood pressure) and opening up the airways to help with the breathing.

The review of adrenaline auto-injectors was initiated at the request of the United Kingdom in April 2014, under Article 31 of Directive 2001/83/EC. This followed a national review of all adrenaline auto-injector products approved in the UK, which concluded that there was no robust evidence that the devices deliver adrenaline into a muscle for all patients.

The review was carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which has adopted the Agency's final opinion. The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 14/08/2015.

Hi Frances, I have been self injecting with the Union Medico Autoinjector ( unionmedico.com/90-super-grip/ ) weekly for over a year now and it is a very good device and totally painless, only the first one was the hardest to actually do and I did this under supervision of my local doctors practice nurse.

A couple of things, the autoinjector does not detect vessels/veins, it is a pressure sensor to ensure you apply sufficient pressure to the local area of skin which stretches it to allow the needle to penetrate more easily.

Always warm up the B12 ampoule before drawing it into the syringe, hold in your palms for a few minutes, this makes it thinner and easier to inject, then change the needle to the smaller injection one and remove all air from the syringe and needle.

Load the syringe into the injector by "arming" the injector to pull the syringe cradle upwards, then release it to allow the needle area to project through the lower shield and then remove the protective cover from the needle itself then "arm" the injector again by pulling the main arm upwards with the syringe until it locks. Look at the injectors manual to ensure you locate the tabs in the cradle correctly to hold the syringe.

I use my thigh areas for the injection site since this offer a much larger potential injection site, if you do this then follow the diagram on the attached link, ( goo.gl/q2JUDm ) this will identify the area location for you, and always sit on a chair with your legs at right angles to the floor.

It helps if you hold the injector with both hands, one on the injector shield to stabilise it and the other to press the fire button which is then used hold it while you push the syringe plunger with the other hand. Push slowly and progressively until it will not move any further then lift the injector, cover the needle again, and wipe the injection area with the swab and give the area a gently rub.

The new research study consists of industry trends, detailed market analysis, product competitiveness analysis, brand positioning analysis, partnerships and collaborations analysis, patent analysis, commercialized autoinjector combination product analysis, early and late stage autoinjector combination product analysis, key opinion leaders analysis, SWOT analysis, and market forecast and opportunity analysis. The growth in the auto injectors market size over the next decade is likely to be the result of an increased adoption of at home care and treatment options along with loss of exclusivity of patents for biologics.

In order to address these challenges, various self-administering drug delivery systems, such as prefilled syringes, large volume wearable injectors, needle free jet injectors have been developed. These drug delivery devices impart greater independence, eliminating the dependence on healthcare providers for drug administration, leading to reduced healthcare costs. However, these drug delivery systems possess certain limitations, such as skin sensitivity issues, manual needle insertion, and needle stick injuries, thereby creating the need for better administration solutions.

Owing to the inadequacies of the conventional drug delivery systems, autoinjectors have steadily gained prominence, especially in the immediate treatment of emergency situations, such as anaphylactic shocks, strokes and rheumatoid arthritis. Autoinjectors are self-injection devices that deliver a specific dose of a drug / therapeutic substance with simple push of a button. The autoinjectors are spring-loaded syringes working on various mechanisms (ranging from simple push-on-skin devices to fully automated button activated technologies) and include pre-measured medication, which eliminates the need to draw medication from a separate vial, thus resolving various injection-related compliance issues faced by the patients.

Further, the audio-visual features in some of the autoinjectors allows the patients to remove the device from the skin when the dose is completed. With the growing adoption of self-administration devices and ongoing advancements in the technologies (focused on integrated needle safety, bluetooth connectivity and monitoring of historical injection logs), the global autoinjectors market is likely to grow, in the foreseen future.

Autoinjectors Market Share Insights

The autoinjectors market research report presents an in-depth analysis of the various companies that are engaged in the global autoinjectors industry, across different segments, as defined in the table below:

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the global autoinjectors market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided informed estimates on the likely evolution of the market during the forecast period, 2024-2035.

Our year-wise projections of the current and future opportunity with the autoinjectors market have been segmented based on relevant parameters, such as usability of autoinjector (disposable autoinjector and reusable autoinjector), route of administration (intramuscular, intravenous and subcutaneous), type of molecule delivered (antibodies, peptides, proteins, small molecules and others), type of actuation mechanism (manual and automatic), volume of container (less than 1 mL, 1-2 mL and more than 2 mL), end-user (ambulatory surgical centres, home care and hospitals and clinics), target indication (anaphylaxis, diabetes, migraine, multiple sclerosis, rheumatoid arthritis, weight loss and others) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).

The opinions and insights presented in the market report were influenced by our discussions with stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

The global autoinjectors market is categorized into intramuscular, intravenous and subcutaneous, based on the route through which the autoinjectors deliver the stored drug. Currently, the autoinjectors for subcutaneous drug delivery segment captures the highest share of the current market and is expected to dominate during the forecast period, followed by auto-injector for intramuscular injection. The increasing interest in subcutaneous autoinjectors can be primarily attributed to the fact that such devices require shorter and thinner needles when compared to deeper intramuscular injections (reducing pain and discomfort to patients), enable faster drug absorption (allowing quicker onset of therapeutic activity) and do not require any training for self-administration (offering convenient delivery of drugs).

3a8082e126